Mechanism of action
Glucose is the primary metabolic fuel for all human cells, particularly neurons and erythrocytes which rely almost exclusively on glucose for energy. After entering cells via facilitated diffusion through GLUT transporters (insulin-dependent GLUT4 in muscle and adipose tissue, insulin-independent GLUT1 and GLUT3 in brain and red blood cells), glucose undergoes glycolysis in the cytoplasm to produce pyruvate.
Pyruvate then enters the mitochondria for oxidative phosphorylation via the citric acid cycle and electron transport chain, yielding approximately 30-32 ATP molecules per glucose molecule under aerobic conditions. In hypoxic conditions or cells lacking mitochondria, glucose undergoes anaerobic glycolysis to produce lactate and 2 ATP molecules.
Brain metabolism: The central nervous system requires approximately 120 grams of glucose daily and cannot utilize fatty acids for energy. Severe hypoglycemia (typically <50-60 mg/dL) causes neuroglycopenic symptoms including confusion, seizures, and loss of consciousness. Intravenous glucose rapidly restores blood glucose levels and reverses these symptoms by providing immediate substrate for cerebral metabolism.
When administered intravenously, glucose bypasses gastrointestinal absorption and directly increases serum glucose concentration. The rate of rise depends on concentration administered (5%, 10%, 25%, 50% solutions available) and infusion rate. Insulin secretion from pancreatic beta cells increases in response to hyperglycemia, promoting cellular glucose uptake and storage as glycogen.
- Always give thiamine before or with glucose in suspected Wernicke encephalopathy to prevent acute deterioration
- Normal CSF glucose is approximately 60% of serum glucose; ratio <0.4 suggests bacterial or TB meningitis
- Hypertonic glucose solutions (>10%) require central venous access to prevent phlebitis and extravasation injury
- Brain relies almost exclusively on glucose; hypoglycemia <50 mg/dL causes neuroglycopenic symptoms (confusion, seizures, coma)
- Renal glucose threshold is 180 mg/dL; glucosuria occurs when this is exceeded due to saturated tubular reabsorption
- Glucose with insulin drives potassium intracellularly and can cause dangerous hypokalemia; monitor and replace K+
- D50W provides 25 grams glucose per 50-mL ampule; many centers now use D10 or D25 to reduce complications
- Stress hyperglycemia in ICU patients is associated with increased mortality; target 140-180 mg/dL in most populations
Indications
Hypoglycemia: The primary emergency indication is treatment of severe hypoglycemia, particularly in diabetic patients who have received excessive insulin or oral hypoglycemic agents, or have inadequate caloric intake. Glucose is also used for hypoglycemia in neonates, especially premature infants with immature glucose homeostasis.
Parenteral nutrition: Glucose solutions provide non-protein calories in total parenteral nutrition (TPN) and partial parenteral nutrition regimens for patients unable to meet caloric needs enterally. Typically administered as 10-70% dextrose solutions depending on access (peripheral versus central venous).
Fluid and electrolyte therapy: Isotonic glucose solutions (5% dextrose in water, D5W) serve as maintenance fluids and vehicles for electrolyte and medication administration. Combined solutions like D5 normal saline or D5 half-normal saline provide both free water and sodium.
Insulin provocative testing: Glucose tolerance testing uses oral glucose loads to assess insulin secretion and diagnose diabetes mellitus and gestational diabetes.
Adjunctive therapy: Used in management of hyperkalemia (combined with insulin to drive potassium intracellularly), and in contrast media protocols. May be given with thiamine in suspected Wernicke encephalopathy to prevent precipitation of acute deficiency.
Pharmacokinetics
Absorption: When given orally, glucose is rapidly absorbed in the proximal small intestine via SGLT1 (sodium-glucose cotransporter) and GLUT2 transporters. Peak blood levels occur within 30-60 minutes. Intravenous administration provides immediate bioavailability.
Distribution: Distributes throughout total body water. Normal fasting serum glucose is 70-100 mg/dL. Volume of distribution approximates 0.6 L/kg. Glucose crosses the placenta and is present in breast milk.
Metabolism: Undergoes intracellular metabolism via glycolysis, glycogenesis (conversion to glycogen in liver and muscle), and lipogenesis (conversion to fatty acids). The liver is the primary site of glucose homeostasis through glycogenolysis and gluconeogenesis.
Excretion: The renal threshold for glucose is approximately 180 mg/dL. Above this level, glucose appears in urine (glucosuria) because tubular reabsorption capacity is exceeded. In normal physiology, virtually all filtered glucose is reabsorbed in the proximal tubule via SGLT2 and SGLT1 transporters.
Half-life: Does not have a traditional half-life as it is continuously metabolized and produced. Serum glucose levels are maintained by balance between glucose input (diet, glycogenolysis, gluconeogenesis) and utilization (cellular metabolism, glycogen synthesis, urinary excretion if hyperglycemic).
Adverse effects
Hyperglycemia: The most common adverse effect, especially with rapid infusion or concentrated solutions. Sustained hyperglycemia can cause osmotic diuresis leading to dehydration, electrolyte disturbances, and in severe cases, hyperosmolar hyperglycemic state. Particularly problematic in critically ill patients, where stress hyperglycemia is associated with increased infection risk and mortality.
Hypoglycemia: Rebound hypoglycemia can occur after abrupt discontinuation of concentrated glucose infusions, as endogenous insulin secretion remains elevated. Gradual tapering is recommended when stopping high-rate infusions.
Hypokalemia and hypomagnesemia: Glucose administration with insulin (endogenous or exogenous) drives potassium and magnesium intracellularly, potentially causing dangerous decreases in serum levels. Cardiac arrhythmias may result.
Phlebitis and thrombosis: Peripheral administration of hypertonic glucose solutions (>10%) causes venous irritation, phlebitis, and thrombophlebitis. Concentrations above 10-12.5% generally require central venous access.
Fluid overload: Excessive administration can cause volume overload, pulmonary edema, and heart failure exacerbation, especially in patients with renal or cardiac dysfunction.
Infection: Prolonged central venous catheter use for concentrated glucose solutions increases risk of catheter-related bloodstream infections. Hyperglycemia itself impairs neutrophil function and wound healing.
Metabolic complications: Prolonged high glucose loads can cause hepatic steatosis, hypertriglyceridemia, and hypercapnia (increased CO2 production from glucose metabolism, problematic in respiratory failure).
Extravasation injury: Infiltration of hypertonic glucose solutions into subcutaneous tissue causes tissue necrosis, particularly in neonates.
Contraindications and warnings
Intracranial hemorrhage: Hypertonic glucose solutions are relatively contraindicated in acute intracranial hemorrhage as they may worsen cerebral edema through osmotic effects when glucose is metabolized.
Diabetic ketoacidosis (DKA) without insulin: Glucose administration without adequate insulin in DKA worsens hyperglycemia and ketoacidosis. Insulin therapy must be initiated before or concurrent with glucose.
Renal impairment: Use cautiously in oliguric or anuric patients due to inability to excrete excess glucose and risk of volume overload. Monitoring of fluid balance is essential.
Cardiac disease: Patients with congestive heart failure or pulmonary edema require careful monitoring as glucose solutions contribute to fluid load.
Thiamine deficiency: Glucose administration can precipitate or worsen Wernicke encephalopathy in thiamine-deficient patients (chronic alcoholism, malnutrition). Thiamine should be given before or with glucose in at-risk populations.
Neonatal considerations: Concentrated glucose solutions must be used cautiously in premature and low birth weight infants due to risk of intraventricular hemorrhage from rapid osmotic shifts and hyperglycemia-induced osmotic diuresis.
Extravasation risk: Use central venous access for solutions exceeding 10-12.5% glucose. Ensure IV line patency before administering hypertonic solutions.
Pregnancy: Generally considered safe. Glucose crosses the placenta; maternal hyperglycemia can cause fetal hyperinsulinemia and macrosomia with chronic exposure, though acute administration for hypoglycemia is appropriate.
Drug interactions
Insulin and oral hypoglycemics: Concurrent use with sulfonylureas, meglitinides, or insulin may require adjustment of antidiabetic medication to prevent hyperglycemia. Conversely, glucose administration can counteract hypoglycemic effects, requiring increased doses.
Corticosteroids: Glucocorticoids cause insulin resistance and increase hepatic glucose production, potentially necessitating higher insulin requirements when glucose is administered. Monitor blood glucose closely.
Diuretics: Thiazide and loop diuretics can cause hyperglycemia through multiple mechanisms (decreased insulin secretion, increased insulin resistance). Combined use may worsen glucose control.
Somatostatin analogs: Octreotide inhibits insulin secretion and may cause hyperglycemia when given with glucose infusions.
Fluoroquinolones: Some fluoroquinolone antibiotics (gatifloxacin, now withdrawn in many countries) can cause dysglycemia (both hyper- and hypoglycemia). Levofloxacin and moxifloxacin have lower risk but monitoring remains prudent.
Mannitol: Co-administration with osmotic diuretics increases osmotic load and risk of dehydration and electrolyte disturbances.
Compatibility considerations: Glucose solutions can cause precipitation when mixed with certain medications. Sodium bicarbonate, ampicillin, and ceftriaxone (in neonates with calcium-containing solutions) are incompatible with certain glucose formulations. Always verify compatibility before mixing.
Clinical pearls
Rule of 15 for hypoglycemia: The outpatient treatment protocol is 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice), recheck glucose in 15 minutes, and repeat if still low. For severe hypoglycemia with altered mental status, intravenous dextrose or intramuscular glucagon is required.
D50 versus D10: A 50-mL ampule of 50% dextrose (D50) provides 25 grams of glucose. Many institutions now prefer diluted solutions (D10, D25) to reduce phlebitis risk and avoid overshoot hyperglycemia. D50 administration carries high risk of extravasation injury.
Central versus peripheral access: Solutions exceeding 900 mOsm/L (approximately 10-12.5% dextrose) require central venous access to prevent phlebitis. TPN with 20-70% dextrose must be given centrally.
Stress hyperglycemia in ICU: Critical illness causes insulin resistance. Target glucose 140-180 mg/dL in most ICU patients; tight control (80-110 mg/dL) increases hypoglycemia risk without clear mortality benefit in most populations.
Thiamine before glucose: In suspected or confirmed thiamine deficiency (alcoholism, malnutrition, hyperemesis), administer 100 mg thiamine IV before glucose to prevent Wernicke encephalopathy. This is a high-yield board concept.
Neonatal hypoglycemia: Term neonates: treat if glucose <40-45 mg/dL in first 4 hours or <50 mg/dL thereafter. Preterm infants have higher thresholds. Avoid rapid boluses of concentrated dextrose; use continuous infusion.
Monitoring in TPN: Patients receiving parenteral nutrition require regular monitoring of serum glucose, electrolytes (especially potassium, magnesium, phosphate), and triglycerides. Refeeding syndrome is a risk when initiating nutrition in malnourished patients.
CSF glucose interpretation: Normal CSF glucose is approximately 60% of serum glucose (measured 30-90 minutes earlier). CSF glucose <40 mg/dL or CSF:serum ratio <0.4 suggests bacterial meningitis, TB meningitis, or fungal meningitis.
Practice questions
1. A 58-year-old man with type 2 diabetes is brought to the emergency department with altered mental status. His wife reports he took his usual glyburide this morning but did not eat breakfast. Fingerstick glucose is 38 mg/dL. After establishing IV access, what is the most appropriate immediate next step?
2. A 42-year-old woman receiving total parenteral nutrition through a central venous catheter develops polyuria, polydipsia, and confusion on hospital day 5. Vital signs: BP 105/70, HR 110, RR 20. Serum studies show: Na+ 152 mEq/L, glucose 520 mg/dL, osmolality 340 mOsm/kg. Urinalysis shows 3+ glucose, no ketones. What is the most likely diagnosis?
3. A 32-year-old man with alcoholism presents to the ED after a seizure. He has been drinking heavily and eating poorly for 2 weeks. Fingerstick glucose is 52 mg/dL. In addition to IV dextrose, which intervention is most important to prevent neurological complications?
Frequently asked questions
How does glucose work in the body?
Glucose is the primary energy substrate for all cells, entering via GLUT transporters and undergoing glycolysis to produce ATP. In aerobic conditions, glucose yields approximately 30-32 ATP molecules through oxidative phosphorylation in mitochondria. The brain requires about 120 grams daily and cannot use fatty acids, making glucose essential for neurological function. When administered intravenously for hypoglycemia, it rapidly restores blood glucose and reverses neuroglycopenic symptoms.
What are the side effects of IV glucose?
The most common side effect is hyperglycemia, especially with rapid or concentrated infusions, which can cause osmotic diuresis and dehydration. Hypertonic solutions (>10%) cause phlebitis and thrombophlebitis when given peripherally. Glucose administration drives potassium intracellularly, potentially causing dangerous hypokalemia and cardiac arrhythmias. Other risks include fluid overload, rebound hypoglycemia after stopping infusions, infection with prolonged central lines, and tissue necrosis if extravasation occurs.
When should you give thiamine with glucose?
Thiamine must be given before or with glucose in patients at risk for thiamine deficiency, including chronic alcoholics, malnourished patients, and those with hyperemesis gravidarum. Glucose administration in thiamine-deficient patients can precipitate or worsen Wernicke encephalopathy by depleting remaining thiamine stores, as thiamine is a cofactor for glucose metabolism. Standard practice is 100 mg thiamine IV before glucose in any at-risk patient.
What is the difference between D5W and normal saline?
D5W (5% dextrose in water) provides free water and 170 calories per liter but is hypotonic once glucose is metabolized, making it useful for treating hypernatremia and providing maintenance fluid. Normal saline (0.9% NaCl) is isotonic and provides sodium and chloride without calories, used for volume resuscitation and avoiding hyponatremia. D5W is not appropriate for acute resuscitation because it does not effectively expand intravascular volume, whereas normal saline remains in the vascular space.
Can you give concentrated glucose through a peripheral IV?
No, glucose concentrations above 10-12.5% (osmolality >900 mOsm/L) should not be given through peripheral IV lines due to high risk of phlebitis, thrombophlebitis, and severe tissue injury if extravasation occurs. Solutions like 25% or 50% dextrose require central venous access. Total parenteral nutrition with 20-70% dextrose must always be administered through a central line. For emergency treatment of hypoglycemia via peripheral access, D10 or D25 is preferred over D50.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: B05CX01WHO ATC/DDD index: V04CA02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.